Personalized Medicine in Psychiatry最新文献

{"title":"Repetitive negative thinking is associated with impaired verbal learning but not executive functioning in individuals with eating disorders","authors":"Grace E. Cardenas,&nbsp;Evan J. White,&nbsp;Namik Kirlic,&nbsp;Tulsa 1000 investigators,&nbsp;Martin P. Paulus,&nbsp;Salvador M. Guinjoan","doi":"10.1016/j.pmip.2021.100090","DOIUrl":"10.1016/j.pmip.2021.100090","url":null,"abstract":"<div><h3>Objective</h3><p>Repetitive negative thinking (RNT) is an important symptom in the development and maintenance of eating disorders (EDs). RNT Research on RNT’s effect on cognition in EDs is scarce. This investigation focused on associations between RNT and cognition in individuals with EDs.</p></div><div><h3>Methods</h3><p><span>Ruminative Response Scale (RRS) was used from Tulsa-1000 study (T-1000) data (eating disorders-ED, Major Depressive Disorder-MDD, and healthy subjects) who were propensity matched to examine associations with cognitive performance. RNT was examined across groups and we quantified the associations between scores for RNT, depression, executive function, and learning/memory from the T-1000 study. A </span>linear regression analysis was conducted to determine predictors of disability.</p></div><div><h3>Results</h3><p>RNT was similar in ED and MDD participants, and more intense than in controls. RNT was significantly correlated with verbal learning/memory in the control (r = 0.514, p = 0.006) and ED groups (r = −0.447, p = 0.020), but this relationship had opposite slopes in either group. Increased RNT was associated with decreased verbal learning/memory ability in ED participants while in controls, increased RNT was associated with increased ability. Comorbid depression in the ED group acted as a potential moderator of the above relationship between RNT and EF. Among ED patients, depressive symptom severity was the best predictor of disability.</p></div><div><h3>Discussion</h3><p>The differential association of RNT with cognitive abilities in ED and MDD patients suggests depression is not a mediator of RNT-mediated cognitive dysfunction in EDs. This necessitates a better understanding of the mechanistic relationship between RNT and diverse types of cognitive functioning.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"31 ","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9359564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of stuttering after administration of methylphenidate - a case report","authors":"Shahriar SheikhBahaei ,&nbsp;Mutahir Farhan ,&nbsp;Gerald A. Maguire","doi":"10.1016/j.pmip.2022.100092","DOIUrl":"10.1016/j.pmip.2022.100092","url":null,"abstract":"","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"31 ","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468171722000023/pdfft?md5=c41e277a56355f5d3d7fc39db95d3c72&pid=1-s2.0-S2468171722000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115847033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The United States index of socioeconomic deprivation for individuals (USiDep)","authors":"Boadie W. Dunlop ,&nbsp;Jeffrey J. Rakofsky ,&nbsp;David Mischoulon ,&nbsp;Helen S. Mayberg ,&nbsp;Becky Kinkead ,&nbsp;Andrew A. Nierenberg ,&nbsp;Thomas R. Ziegler ,&nbsp;Maurizio Fava ,&nbsp;Mark H. Rapaport","doi":"10.1016/j.pmip.2022.100091","DOIUrl":"10.1016/j.pmip.2022.100091","url":null,"abstract":"<div><h3>Background</h3><p>Individuals experiencing socioeconomic deprivation consistently demonstrate poorer physical and mental health. Income alone is inadequate as a measure of socioeconomic status (SES); a better measure for assessing the deprivation status of individuals is needed.</p></div><div><h3>Methods</h3><p>The New Zealand Index of Socioeconomic Deprivation for Individuals, a validated, eight-item measure of deprivation, was modified to create the United States Index of Socioeconomic Deprivation for Individuals (USiDep). The questionnaire was administered to patients with major depressive disorder participating in two clinical trials. Spearman’s correlation coefficients evaluated associations between USiDep scores with income and other measures associated with deprivation.</p></div><div><h3>Results</h3><p>The USiDep was completed by 118 participants, demonstrating adequate internal consistency (Crohnbach’s alpha = 0.766) and strong item-total correlations. USiDep scores were moderately correlated with past-year personal income (Spearman’s rho = -0.362, p &lt; .001) and several other measures related to deprivation, including body mass index, level of education, quality of life, severity of childhood traumatic events, self-reported physical health, and negative life events. Patients scoring 5 on the USiDep (the highest possible score, indicating greater deprivation) had significantly lower rates of remission after 12 weeks of treatment than those scoring ≤ 4 (1/12, 8.3% vs 40/98, 40.8%, respectively, p = .03), whereas the lowest income group showed no significant associations with outcomes.</p></div><div><h3>Conclusion</h3><p>The USiDep is a valid, brief questionnaire for assessing SES that has utility for clinical research and may serve as a predictor of treatment outcomes in clinical trials. Validation of the USiDep in healthy controls and other medically and psychiatrically ill populations is warranted.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"31 ","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/a0/nihms-1771841.PMC9355266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40701389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ziconotide-induced psychosis in patient without previous psychiatric history: A case report","authors":"Amanda Su ,&nbsp;Hannah Johnson ,&nbsp;Colleen Taylor ,&nbsp;Sarah Oros","doi":"10.1016/j.pmip.2021.100086","DOIUrl":"10.1016/j.pmip.2021.100086","url":null,"abstract":"","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127855275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized functional connectivity analysis in responders and nonresponders to ketamine and electroconvulsive therapy: A case series","authors":"Maria Lucia Fazzito ,&nbsp;Juan José Gonzalez ,&nbsp;Leticia Fiorentini ,&nbsp;Marina Leiman ,&nbsp;Adriana Pérez ,&nbsp;Elsa Costanzo ,&nbsp;Mirta F. Villarreal ,&nbsp;Salvador M. Guinjoan","doi":"10.1016/j.pmip.2021.100082","DOIUrl":"10.1016/j.pmip.2021.100082","url":null,"abstract":"<div><h3>Objective</h3><p><span><span>Major depressive disorder<span><span> is a common medical problem, frequently resistant to antidepressant </span>treatments. We sought to describe </span></span>functional connectivity correlates of response and non-response to rapid-acting antidepressants </span>in patients with treatment-resistant depression.</p></div><div><h3>Methods</h3><p><span>We performed an MRI-based, BOLD functional connectivity analysis on three patients with treatment-resistant depression, with varying degrees of response to electroconvulsive therapy (ECT) or intravenous subanesthetic </span>ketamine.</p></div><div><h3>Results</h3><p>Response to treatment was associated with an increase of positive correlations and increased connectivity of bilateral frontal, subcortical, right temporal and right occipital regions. Treatment nonresponse was associated with an increase in negative correlations between frontal lobes and their respective contra- and ipsilateral parietal and occipital lobes.</p></div><div><h3>Conclusion</h3><p>Response to rapid-acting treatments was associated in this case series to increased functional connectivity, especially in homologous regions of both hemispheres. If replicated in a bigger sample, this correlate of response can provide insights into mechanisms of rapid-acting antidepressant treatment response.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129495237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-diagnostic study of adherence to ecological momentary assessment: Comparisons across study length and daily survey frequency find that early adherence is a potent predictor of study-long adherence","authors":"Sara E. Jones ,&nbsp;Raeanne C. Moore ,&nbsp;Amy E. Pinkham ,&nbsp;Colin A. Depp ,&nbsp;Eric Granholm ,&nbsp;Philip D. Harvey","doi":"10.1016/j.pmip.2021.100085","DOIUrl":"10.1016/j.pmip.2021.100085","url":null,"abstract":"<div><h3>Background</h3><p>Ecological momentary assessment (EMA) offers a highly valid strategy to assess everyday functioning in people with severe mental illness. Adherence is generally good, but several questions regarding the impact of study length, daily density of sampling, and symptom severity on adherence remain.</p></div><div><h3>Methods</h3><p>EMA adherence in two separate studies was examined. One sampled participants with schizophrenia<span> (n = 106) and healthy controls (n = 76) 7 times per day for 7 days and the other sampled participants with schizophrenia (n = 104) and participants with bipolar illness (n = 76) 3 times per day for 30 days. Participants were asked where they were, who they were with, what they were doing and how they were feeling in both studies. The impact of rates of very early adherence on eventual adherence was investigated across the samples, and adherence rates were examined for associations with mood state and most common location when answering surveys.</span></p></div><div><h3>Results</h3><p>Median levels of adherence were over 80% across the samples, and the 10th percentile for adherence was approximately 45% of surveys answered. Early adherence predicted study-long adherence quite substantially in every sample. Mood states did not correlate with adherence in the patient samples and being home correlated with adherence in only the bipolar sample.</p><p><strong>Implications</strong>: Adherence was quite high and was not correlated with the length of the study or the density of sampling per study day. There was a tendency for bipolar participants who were more commonly away from home to answer fewer surveys but overall adherence for the bipolar patients was quite high. These data suggest that early nonadherence is a potential predictor of eventual nonadherence and study noncompletion.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100085"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39431777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral kynurenines as biomarkers and targets for prevention and treatment of psychiatric conditions associated with SARS-CoV-2 infection","authors":"Gregory Oxenkrug,&nbsp;Paul Summergrad","doi":"10.1016/j.pmip.2021.100088","DOIUrl":"10.1016/j.pmip.2021.100088","url":null,"abstract":"<div><p>Present review focuses on the possible role of tryptophan (Trp) – kynurenine (Kyn) pathway in the mechanism(s) of COVID-19 associated psychiatric complications. SARS-CoV-2 infection, that causes COVID-19, triggers overproduction of interferon-gamma (IFNG), a pro-inflammatory cytokine. IFNG activates <em>indoleamine 2,3-dioxygenase-1</em> (<em>IDO</em>), enzyme that catalyzes Trp conversion into Kyn, and enzymes of down-stream Kyn pathway that catalyze Kyn conversion into 3-hydroxykynurenine, kynurenic and anthranilic acids in brain and peripheral organs. We reviewed data on SARS-CoV-2 - IFNG – induced changes of peripheral Trp – Kyn pathway, considering their translational potential for personalized psychiatric care. Elevated blood levels of Trp – Kyn pathway metabolites were correlated with the severity of symptoms and predicted the negative outcomes in COVID-19 patients. Association of Trp – Kyn pathway up-regulation with psychiatric complication in non-COVID-19 patients suggests that activation of these pathways contribute to the mechanism(s) of COVID-19 associated psychiatric conditions as well. Increased risk of psychiatric complications in carriers of T (high producer) allele of polymorphic IFNG gene and elevation of serum levels of Kyn and its metabolites in interferon-alpha treated hepatitis C virus patients provides further support for such a suggestion. Assessment of blood levels of Kyn and its metabolites, and polymorphism of Trp – Kyn pathway genes might be developed into personalized biological markers predicting gender/aging dependent individual’s risk of psychiatric complications in COVID-19 patients. Up-regulation of IFNG and IDO is necessary for anti-viral protection. Therefore, inhibition of down-stream Kyn pathway should be considered as a new target for prevention/treatment of COVID-19 and COVID-19-associated psychiatric complications.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100088"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S246817172100020X/pdfft?md5=c6c57e63faacccf53d58f38ece9a1a23&pid=1-s2.0-S246817172100020X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115584015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disrupted copper homeostasis: Pathogenic factor in autism spectrum disorder and side effect of valproic acid","authors":"Stephen I. Deutsch ,&nbsp;David R. Spiegel ,&nbsp;Jessica A. Burket","doi":"10.1016/j.pmip.2021.100087","DOIUrl":"10.1016/j.pmip.2021.100087","url":null,"abstract":"<div><p>A 23 year old male diagnosed with autism spectrum disorder and treated with valproic acid presented with acute onset of hepatic failure; he died less than two months later. Laboratory studies led to a diagnosis of Wilson Disease. The case raised questions about a possible pathogenic role of disrupted copper homeostasis in ASD, and exacerbation of this disruption as a result of treatment with valproic acid. Screening for abnormalities of copper homeostasis may stimulate strategies for therapeutic targeting of a contributing etiological factor and avoidance of contraindicated medications.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100087"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130710728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between duration of untreated psychosis and working memory in early-onset psychotic disorders","authors":"Joko Cahyo Baskoro ,&nbsp;Ivana Ariella Nita Hadi ,&nbsp;Maulidia Ekaputri ,&nbsp;Noorhana Setiawati Winarsih","doi":"10.1016/j.pmip.2021.100084","DOIUrl":"10.1016/j.pmip.2021.100084","url":null,"abstract":"<div><p>Psychotic disorders are morbid mental disorders<span> that impair working memory. Theory suggests that longer duration of untreated psychosis (DUP) results in worse working memory. However, results from previous studies are contradictory, with no study having been conducted in children. This study aims at finding out the association between duration of untreated psychosis and working memory in children. This is a cross-sectional study with 45 subjects. DUP was collected from medical records whereas working memory was measured using digit span backward raw score. Average digit span backward scores of subjects was 3.7 ± 1.18. Analysis using Spearman test showed no significant association (p = 0.128) between DUP and working memory. In conclusion, there is no association between DUP and working memory in children, therefore we recommend that psychiatrists pay attention to working memory impairment in all pediatric patients with psychotic disorders, regardless of their DUP.</span></p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmip.2021.100084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123235253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deiodinase variation and liothyronine treatment interaction to accelerate ECT response in major depression: Pilot data and implications for thyroid pharmacogenomic testing in mood disorders","authors":"Nicolas A Nuñez ,&nbsp;Christopher Sola ,&nbsp;Simon Kung ,&nbsp;Balwinder Singh ,&nbsp;Aysegul Ozerdem ,&nbsp;Marin Veldic ,&nbsp;Paul E. Croarkin ,&nbsp;Katherine M. Moore ,&nbsp;Hannah K. Betcher ,&nbsp;Jennifer L. Vande Voort ,&nbsp;Jennifer R. Geske ,&nbsp;Joanna M. Biernacka ,&nbsp;Teresa A. Rummans ,&nbsp;Rebecca S Bahn ,&nbsp;Mark A. Frye","doi":"10.1016/j.pmip.2021.100089","DOIUrl":"10.1016/j.pmip.2021.100089","url":null,"abstract":"<div><h3>Background</h3><p>Concurrent liothyronine treatment has been shown to accelerate time to response in patients treated for major depression. However, the relationship between genetic variation in deiodinase and T3 treatment response has received little investigation.</p></div><div><h3>Methods</h3><p>This is a post-hoc analysis of a randomized, double-blind, placebo-controlled trial of concurrent liothyronine (T3-Cytomel®, n = 23; mean dose 46.3 ± 3.3 mcg) in patients with major depression where a clinical recommendation was made to pursue ECT. The primary outcome measure was time to 50% reduction in depressive symptoms. Multivariable linear models were used to examine effect of T3 and placebo and genetic variants as predictors of change in HAMD24 and number of ECT treatments.</p></div><div><h3>Results</h3><p>Survival analysis did not show a significant effect for the T3 + ECT group achieving a faster time to response compared to placebo + ECT (p + ECT). Survival analysis for RUL lead placement alone showed a significant effect for the T3 + ECT group achieving a faster time to response compared to p + ECT (p = 0.01) with significantly fewer ECT treatments (p = 0.03). Carriers of the functional SNP rs11206244 gene DI01-C785T minor allele (TT and CT) vs. non-carriers (CC), showed fewer ECT treatments in the T3 + ECT group, compared to p + ECT (5.3 ± 1.0 vs. 8.3 ± 2.1, p = 0.045).</p></div><div><h3>Conclusions</h3><p>These pilot data identify clinically relevant genetic variation in DI01- C785T contributing to an accelerated response time, but not an overall greater symptom reduction. Exogenous T3 supplementation may be therapeutic by attenuating a baseline DI01 relative functional deficit which functionally reduces peripheral conversion of T4 to biologically active T3. Further work is encouraged to assess genetic variation of thyroid deiodinase enzymes in larger samples of depressed patients to better optimize accelerating strategies to ECT and more broadly, thyroid augmentation strategies in major depressive and bipolar disorders.</p></div>","PeriodicalId":19837,"journal":{"name":"Personalized Medicine in Psychiatry","volume":"29 ","pages":"Article 100089"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468171721000211/pdfft?md5=c5e0abd0b4252999dfe9c21ae710fe2b&pid=1-s2.0-S2468171721000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124689429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}